Bioregulator Peptides
Cartalax
Commonly used for
Joint SupportCartilage Health
What is it?
Cartalax is a synthetic peptide bioregulator proposed to support cartilage and connective tissue health, from the same research tradition as other short bioregulator peptides.
Mechanism of action: Proposed support for chondrocyte (cartilage cell) function (preclinical); Proposed regulation of connective tissue gene expression
What do people use it for?
Proposed indications: Cartilage health (preclinical); Joint support
How is it used? / Dosing
Typical clinical dosing schedule: No established clinical dosing. Human use has been limited to early-phase research.
Administration: Subcutaneous or intramuscular injection (research settings) — No established clinical dosing
How does it compare?
Compare with:
How well does it work? / Evidence
? Emerging / limited evidence
An "emerging / limited evidence" rating means rigorous research hasn't caught up yet -- not that this peptide doesn't work. Many peptides in this category are newer or simply understudied rather than proven ineffective.
Evidence rating: ⭐⭐☆☆☆ — Preclinical bioregulator-peptide research suggests effects on cartilage cell (chondrocyte) function in animal models; human clinical trial data are lacking.
Safety & side effects
Common side effects: Human safety profile remains incompletely characterized.
Serious risks: Unknown long-term safety.
Legal & regulatory status
Legal status: Not FDA-approved for human use. This is a research compound, not a medication — any use should only occur under the direction of a licensed healthcare provider, and its legal availability varies and changes frequently. Verify current status independently before considering use.
Regulatory status: Research peptide • Not FDA approved
Who should avoid it?
Contraindications: Not established. Avoid in:; Pregnancy; Active malignancy; Uncontrolled illness outside research settings
Pregnancy & breastfeeding: Avoid.